Jenome Biophar Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 19-12-2024
- Paid Up Capital ₹ 0.10 M
as on 19-12-2024
- Company Age 10 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
as on 19-12-2024
- Revenue 2.61%
(FY 2022)
- Profit 124.67%
(FY 2022)
- Ebitda 354.20%
(FY 2022)
- Net Worth 46.92%
(FY 2022)
- Total Assets 9.30%
(FY 2022)
About Jenome Biophar
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.00 M.
Sudhakar Arya and Ruchi Kapur serve as directors at the Company.
- CIN/LLPIN
U51397DL2014PTC264130
- Company No.
264130
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jan 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Jenome Biophar Private Limited offer?
Jenome Biophar Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Medicine, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Nutraceuticals & Dietary Supplements, Mineral Supplement, Multivitamin Tablets & Capsules, Capecitabine Tablets, Epirubicin Injection, Imatinib Tablet.
Who are the key members and board of directors at Jenome Biophar?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudhakar Arya  | Director | 28-Jan-2014 | Current |
| Ruchi Kapur | Director | 08-Feb-2016 | Current |
Financial Performance of Jenome Biophar.
Jenome Biophar Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 2.61% increase. The company also saw a substantial improvement in profitability, with a 124.67% increase in profit. The company's net worth Soared by an impressive increase of 46.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jenome Biophar?
In 2022, Jenome Biophar had a public holding of 2.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 01 Mar 2020 | ₹5.00 M | Open |
How Many Employees Work at Jenome Biophar?
Jenome Biophar has a workforce of 1 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jenome Biophar, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jenome Biophar's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
